Chinese pharmaceutical company Sichuan Kelun Pharmaceutical has issued a public offering of 2018’s first-tranche medium-term notes to raise CNY500m ($78.96m).

The notes carry an interest rate of 6.2% and are due 26 January 2021.

Sichuan Kelun plans to use the proceeds for debt repayment and working capital needs.

China Postal Savings Bank is the lead underwriter for the transaction.

Cerus has issued an underwritten public offering of shares of its common stock to raise $50m.

The underwriter will be granted a 30-day option to buy an additional $7.5m shares.

The US-based biomedical products company will use the proceeds for the development and commercialisation of its INTERCEPT Blood System in the US and for other general corporate needs.

OptiBiotix Health has issued 354,162 ordinary shares priced at £0.08 ($0.11) a share in a private placement to raise £0.03m ($0.04m).

Cairn Financial Advisers and finnCap were the financial advisors for the transaction.

OptiBiotix Health is a UK-based life sciences company developing treatments related to obesity, high cholesterol and diabetes.

“OptiBiotix Health has issued 354,162 ordinary shares priced at £0.08 ($0.11) a share in a private placement to raise £0.03m ($0.04m).”

Canadian biotechnology company Avicanna has completed the private placement of second non-brokered units to raise C$4.75m ($3.85m).

The company plans to use the proceeds towards research and development, product licensing and financing of phase one construction of a production facility located in Santa Marta, Colombia.

Israeli pharmaceutical company, Teva Pharmaceutical Industriesalong with its subsidiaries, plans to raise $5bn through a public offering of debt securities, purchase contracts and units.

The company will use the proceeds towards general corporate purposes, working capital and repayment of indebtedness.

Kirkland & Ellis was appointed as the legal advisor for the transaction.

Irish biopharmaceutical company Amarin has issued American Depositary Shares (ADS) in a public offering to raise $70m.

The company will also grant underwriters a 30-day option to buy an additional $10.5m-worth ADSs.

Amarin plans to use the proceeds towards medical education and market awareness initiatives.